CYCS and colonic neoplasm: The supporting evidence of LDH release, ROS production, MMP suppression, elevation in the level of cytochrome c, and activation of caspases 3/7 and 9 demonstrated the promising anticancer activity of the Cu(BrHAP)2 Schiff base compound against the HT-29 colon cancer cell line via the intrinsic mitochondrial pathway.